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The family of p21-activated protein kinases (PAKs) is composed of
serine–threonine kinases whose activity is regulated by the small
guanosine triphosphatases (GTPases) Rac and Cdc42. In mamma-
lian cells, PAKs have been implicated in the regulation of mitogen-
activated protein cascades, cellular morphological and cytoskeletal
changes, neurite outgrowth, and cell apoptosis. Although the
ability of Cdc42 and Rac GTPases to activate PAK is well established,
relatively little is known about the negative regulation of PAK or
the identity of PAK cellular targets. Here, we describe the identi-
fication and characterization of a human PAK-interacting protein,
hPIP1. hPIP1 contains G protein b-like WD repeats and shares
sequence homology with the essential fission yeast PAK regulator,
Skb15, as well as the essential budding yeast protein, MAK11.
Interaction of hPIP1 with PAK1 inhibits the Cdc42yRac-stimulated
kinase activity through the N-terminal regulatory domains of
PAK1. Cotransfection of hPIP1 in mammalian cells inhibits PAK-
mediated c-Jun N-terminal kinase and nuclear factor k B signaling
pathways. Our results demonstrate that hPIP1 is a negative regu-
lator of PAK and PAK signaling pathways.
The p21-activated kinases (PAKs) are members of a family ofserine–threonine protein kinases that are regulated by the
small GTPases, Cdc42 and Rac (1–4). There are four known
PAK isoforms (PAK 1–4) that are differentially expressed in
mammalian tissues (3, 4). Ste20, Cla4, and Shks are PAK
homologs in the budding yeast and the fission yeast, respectively
(5, 6). PAKs regulate diverse cellular functions, including gene
expression, cytoskeletal actin assembly, mitogen-activated pro-
tein kinase (MAPK) pathways, neurite outgrowth, cell cycle
control, and cell apoptosis (7–16). In mammalian cells, PAKs
have been reported to activate the c-Jun N-terminal kinase
(JNK) and nuclear factor k B (NF-kB) pathways under different
conditions (9, 17–20). Constitutively activated PAK mutants can
activate the JNK–MAPK cascade, leading to transcriptional
control (9). In HIV1-infected cells, PAKs bind the HIV Nef
protein and play a critical role in cellular activation by Nef and
in HIV pathogenesis (21, 22).
PAKs share a common structural organization consisting of an
N-terminal half that includes autoregulatory and interaction
segments and a C-terminal kinase domain. Both the crystal and
solution structures of PAK show that the protein forms dimers
(two autoregulatory fragments and two kinase domains) held
together by the interaction of the autoregulatory fragments (23).
Binding of GTPases (Cdc42yRac) to the N-terminal regulatory
domains triggers a series of conformational changes that lead to
the disruption of the PAK dimer and the activation of the kinase.
Regulation of PAK activity depends on both the autoregulatory
domains of the molecule and the state of Thr-423 phosphory-
lation in the kinase-activation domain (24, 25). Mutations within
the autoregulatory domains and at the autophosphorylation site
(Ser-423 3 Glu) produce constitutively active PAK (8, 24, 26).
The apparent multiplicity of PAK structure and PAK-
mediated signaling pathways suggests that PAK activity must be
tightly regulated. PAKs can be activated in vivo and in vitro by
binding to GTP-bound Cdc42 and Rac. In response to tyrosine
phosphorylation, adaptor protein Nck can recruit PAK1 to the
membrane to increase its activity and specificity (27–29). In the
budding yeast Saccharomyces cerevisiae, the PAK1 homologue
Ste20 is involved in transmitting the mating-pheromone signal
from the Gbg-subunits of a heterotrimeric G protein to a
downstream MAPK cascade (30). Binding of Gb with the
noncatalytic C-terminal region of Ste20 is essential for the
activation of the MAPK cascade in signaling from the mating
factor receptor (31). Recently, a family of PAK-interacting
exchange factors (PIXs) for Rac and Cdc42 were identified as
binding tightly to the fourth proline-rich domain in the N
terminus of PAK (32, 33). PIX can regulate PAK activity both
by catalyzing GTP exchange on Cdc42yRac and by direct binding
to PAK (34). However, we still know little about the negative
modulation of PAK and PAK-mediated signaling pathways. In
this report, we describe the identification and characterization of
a human PAK1-interacting protein, hPIP1. Sequence analysis of
hPIP1 indicates that the protein contains five G protein b-like
WD repeats and shares sequence homology with the protein
MAK11 in budding yeast (35) and with the PAK regulator Skb15
in fission yeast (37), both of which are essential for cell growth.
hPIP1 interacts with PAK1 both in vivo and in vitro. Further-
more, transfection of hPIP1 in mammalian cells inhibits the
Cdc42-stimulated PAK kinase activity, PAK-mediated JNK, and
NF-kB signaling pathways presumably through binding to the
N-terminal regulatory domains of PAK1. These results suggest
that hPIP1 is a negative regulator of PAK and PAK signaling
pathways.
Materials and Methods
Cloning of hPIP1 and Construction of Expression Plasmids. A yeast
two-hybrid system was used to clone hPIP1. Phospholipase C
(PLC)-b3 was subcloned into the Gal4 DNA-binding domain in
the vector pGBKT7. The bait vector was transformed into the
yeast strain AH109. A pretransformed human heart Match-
Maker cDNA library (CLONTECH) was screened. Interacting
proteins were selected on synthetic plates lacking four different
nutrients (tryptophan, leucine, histidine, and adenine). The
interaction was further tested by the activation of a second
reporter gene, lacZ, by filter assays. For expression of hPIP1 in
bacteria, hPIP1 was expressed as glutathione S-transferase
(GST)-fusion protein by subcloning into pGEX-2T (Amersham
Pharmacia). For mammalian expression, hPIP1 was subcloned
into a FLAG-tagged vector, pCMV-Tag2 (Stratagene).
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Protein Kinase Assays. Cdc42V12 (1 mg) was cotransfected into
COS-7 cells with PAK1 (2 mg) or the mutant PAK1T423E (2 mg)
and hPIP1 (2 mg) expression vectors, where appropriate. Hem-
agglutinin (HA)-tagged PAK1 or HA-JNK was immunoprecipi-
tated by using anti-HA monoclonal antibody 12CA5 (Roche
Molecular Biochemicals) or rabbit anti-PAK1 antibody. The
immunoprecipitates were washed three times in Nonidet P-40
lysis buffer, once in 0.5 M LiCl, and then once in protein kinase
buffer (50 mM Hepes, pH 7.5y10 mM MgCl2y1 mM DTTy0.05%
Triton X-100). The immunoprecipitates were then incubated at
30°C for 30 min in 50 ml of protein kinase buffer. For in vitro
PAK1 activation, 4 mg of Cdc42 bound to the g-thio analog of
GTP (GTPgS-Cdc42) was added to the reaction with or without
4 mg of hPIP1. Samples were resolved on SDSy12% PAGE and
processed for autoradiography.
In Vitro Translation, Binding Assays, and Immunoprecipitation. In
vitro transcription and translation of proteins were performed
with a kit essentially according to the manufacturer’s instruc-
tions (Promega). Briefly, plasmids (1–2 mg per reaction) were
added to a reaction mixture that included 25 ml of rabbit
reticulocyte lysate, 2 ml of reaction buffer, 1 ml of T3 RNA
polymerase, 1 ml of amino acid mixture minus methionine (1
mM), 4 ml of [35S]methionine (10 mCiyml; 1 Ci 5 37 GBq),
ribonuclease inhibitor (40 unitsyml), and nuclease-free H2O to a
final volume of 50 ml. The reactions were incubated at 30°C for
90 min. The in vitro translated proteins were then used for in vitro
binding assays. The interactions of in vitro translated proteins
with GST-PAK1 fusion proteins were directly examined by
autoradiography.
Binding of PAK1 with hPIP1 in mammalian cells was exam-
ined by immunoprecipitation and by Western blot analysis.
Briefly, cells were lysed with a cell extraction buffer (1% Nonidet
P-40y20 mM TriszHCl, pH 7.5y150 mM NaCly1 mM EDTAy1
mM Na3VO4y2 mM PMSFy20 mg/ml aprotininy3 mg/ml leupep-
tiny3 mg/ml pepstatin) and immunoprecipitated with the indi-
cated antibodies. Anti-PAK1 and anti-FLAG immunocomplexes
were recovered by using protein A and G beads (Sigma). All
immunoprecipitates were washed four times with lysis buffer and
were separated by SDSyPAGE and then transferred to poly(vi-
nylidene difluoride) (PVDF) membranes (Millipore). After
incubation in TBST (20 mM TriszHCl, pH 7.5y500 mM NaCly
0.02% Tween-20) containing 2% BSA or 10% dry milk powder,
the membranes were probed with the indicated antibodies and
visualized with the SuperSignal West Pico detection system
(Pierce).
Transient Transfection and Reporter Assays. COS-7 or mouse em-
bryonic fibroblast cells were seeded in DMEM containing 10%
(volyvol) FBS 24 h before transfection. Cells were transfected
with Lipofectamine (BRL) in serum-free Opti-MEM (BRL). A
cytomegalovirus vector pCIS encoding b-galactosidase was used
to maintain a constant amount of cDNA and equalize the
amount of a particular cDNA in each set of experiments. For
transcriptional reporter assays, the PathDetect AP-1 cis-
Reporting System (pAP1-Luc, 73 AP-1 enhancer elements) and
the PathDetect NF-kB cis-Reporting System (pNF-kB-Luc, 53
NF-kB enhancer elements) from Stratagene were used in the
assays. Luciferase assays were performed with a kit as recom-
mended by the manufacturer’s instructions (Promega). The data
presented are the mean of three individually transfected wells.
The experiments were performed at least three times.
Immunocytochemistry. Cells were fixed with 4% (volyvol) para-
formaldehyde for 20 min, blocked with 10% (wtyvol) BSA, and
incubated with monoclonal antibody against the FLAG epitope
(M2 monoclonal, Sigma). Actin filaments were labeled by rho-
damine-conjugated phalloidin. Fluorescent images of cells were
captured on a Sony charge-coupled device camera mounted on
a Nikon E600 microscope using PHOTOSHOP imaging software.
Results
Cloning and Expression of hPIP1. To understand the regulation of
PAK signaling pathways, we examined the interaction of PAK
with a human protein, hPIP1 (human PAKyPLC-interacting
protein 1). hPIP1 was initially identified from a yeast two-hybrid
screen by using PLC-b3 as a bait. Sequence analysis revealed that
hPIP1 contains five putative WD repeat domains like the G
protein b-subunits (Fig. 1 A and B). On the other hand, hPIP1
also shares more than 25% sequence identity and a highly
positively charged C-terminal domain with the protein MAK11
in the budding yeast Saccharomyces cerevisiae (35) and Skb15
(the yeast PAK-binding protein) in the fission yeast Schizosac-
charomyces pombe (ref. 37; Fig. 1C). Sequence homology with
the fission yeast PAK (Shk1)-binding protein Skb15 suggests that
hPIP1 may interact with human PAK and modulate PAK-
mediated signaling pathways.
To analyze the tissue distribution of hPIP1, we examined the
expression of the protein in different human tissues by using
Northern blot analysis. As shown in Fig. 2, hPIP1 is expressed in
most human tissues, with a higher level of expression in brain,
heart, and muscle.
hPIP1 Interacts with PAK1 in Vitro and in Vivo. To determine
whether hPIP1 interacts with PAK, we cotransformed a yeast
two-hybrid test strain with vectors expressing Gal4 DNA-binding
domain hPIP1 fusion protein (pGBD-hPIP1) and Gal4 activa-
Fig. 1. Amino acid sequence and domain structure of hPIP1. (A) Deduced
amino acid sequence of hPIP1. (B) Comparison of WD repeats of hPIP1 with G
protein b1-subunit. :, identical residues; 1, conservative changes. (C) Domain
structures of hPIP1 and two yeast homologs, Skb15 in Schizosaccharomyces
pombe and MAK11 in Saccharomyces cerevisiae. These three proteins contain
five or six WD repeats and a C-terminal positively charged domain.








tion domain PAK1 fusion protein (pGAD-PAK1). GBD-hPIP1
interacts with GAD-PAK1 in yeast cells as shown by activation
of the nutritional reporter gene HIS3 (growth of yeast cells on
selective medium plates deficient in tryptophan, leucine, and
histidine) (Fig. 3A) and by activation of the lacZ reporter gene,
which encodes b-galactosidase (Fig. 3B). To test whether hPIP1
can bind directly to PAK1 in vitro, PAK1 was expressed as GST
fusion protein in bacteria and tested for interaction with in vitro
transcribed and translated [35S]methionine-labeled hPIP1. GST
alone failed to bind to hPIP1, whereas GST-PAK1 fusion protein
bound labeled hPIP1 (Fig. 3C), suggesting that hPIP1 is able to
interact with PAK1 in vitro. To further demonstrate that hPIP1
interacts with PAK1 in mammalian cells, we transiently coex-
pressed FLAG epitope-tagged hPIP1 and PAK1 in COS-7 cells
and assayed for complex formation by using immunoprecipita-
tion and Western blot analysis. As shown in Fig. 3 D and E,
association of hPIP1 with PAK1 in COS-7 cells was demon-
strated by coimmunoprecipitation using either anti-PAK1 anti-
body or anti-FLAG M2 monoclonal antibody, suggesting that
hPIP1 interacts with PAK1 in mammalian cells.
Inhibition of PAK1 Activity by hPIP1. Because PAKs are directly
activated by Cdc42yRac, we performed a series of biochemical
experiments to assess the effect of hPIP1 on Cdc42-mediated
PAK activity (Fig. 4A). COS-7 cells were transfected with
Myc-tagged PAK1 in the presence or absence of dominant active
Cdc42 and hPIP1, respectively. Cells were lysed and assayed for
PAK kinase activity by an immune complex kinase assay in which
myelin basic protein was used as a substrate (24, 25). Cotrans-
fection of PAK1 with Cdc42 dominant active mutant Cdc42V12
resulted in a 10-fold increase in PAK1 kinase activity (Fig. 4A).
However, the presence of hPIP1 almost completely blocked the
Cdc42-induced PAK1 activation (Fig. 4A). Titration of hPIP1
revealed progressive inhibition of the activity of PAK1 kinase
(data not shown), whereas hPIP1 had little effect on a consti-
tutively active PAK1 kinase mutant (PAK1T423E; Fig. 4B).
These results suggest that hPIP1 inhibits the activation of PAK1
by activated Cdc42 protein in mammalian cells. To confirm the
inhibitory effect of hPIP1 on PAK1 activation, we further tested
whether PAK1 kinase activity could be inhibited in vitro by the
hPIP1. Purified PAK1 was mixed with recombinant GST-Cdc42
and hPIP1. Fig. 4C demonstrates that the stimulation of PAK1
kinase by GTPgS-Cdc42 was reduced by the addition of hPIP1.
Together, these data indicate that hPIP1 inhibits the specific
activation of PAK1 by the Cdc42 GTPases.
hPIP1 Regulates PAK1-Induced JNK. PAKs have been shown to
activate JNK in the MAPK pathways, as well as the NF-kB
signaling pathway. To define the role of hPIP1 on PAK-mediated
JNK-signal transduction, we tested whether hPIP1 affects the
activation of JNK by PAK. As shown in Fig. 4D, overexpression
of activated Cdc42 and PAK1 significantly increased the kinase
activity of JNK by ’10-fold as assayed by the phosphorylation
of GST-cJun. Activation of JNK by dominant activated Cdc42
mutant Cdc42V12 alone occurred presumably through the ac-
tivation of endogenous PAK. However, coexpression of hPIP1
dramatically blocked the activation of JNK either by activated
Cdc42 (Fig. 4D, lane 3) or by Cdc42 and PAK (Fig. 4D, lane 5),
suggesting that hPIP1 inhibits both the endogenous and the
transiently expressed Cdc42yPAK-induced JNK signaling. To
further confirm the effect of hPIP1 on JNK signaling, we used
a transcriptional reporter (pAP 1-Luc) to assay for activation of
the JNK signaling pathway. Expression of PAK1 with the AP
1-Luc reporter increased the luciferase activity by approximately
2-fold, whereas cotransfection of PAK1 with a dominant active
mutant of Cdc42 V12 into the cells enhanced the PAK-induced
AP-1 activation by ’4- to 5-fold (Fig. 5A). However, in the
presence of hPIP1, the Cdc42-PAK-mediated AP-1 luciferase
Fig. 2. Northern blot analysis of hPIP1 expression in different human tissues.
Multiple Tissue Northern (MTN) blots were prepared from the purified
poly(A)1 RNA and blotted onto a positively charged nylon membrane (CLON-
TECH). The amount of RNA on an MTN blot membrane is adjusted so that the
b-actin hybridization signal is of comparable intensity in every lane (CLON-
TECH). RNA was isolated from following human tissues: 1, brain; 2, heart; 3,
muscle; 4, colon; 5, thymus; 6, spleen; 7, kidney; 8, liver; 9, small intestine; 10,
placenta; 11, lung; 12, peripheral blood leukocytes. The size of hPIP1 cDNA was
estimated to be ’2.4 kb with minor bands at 4.1 kb.
Fig. 3. hPIP1 specifically binds to PAK1 in vitro and in vivo. (A) hPIP1
cotransformed with PAK1 or control plasmids, pVA3–1 and pTD1–1, respec-
tively. pVA3–1 and pTD1–1 are positive control plasmids that encode the
murine p53 protein and the simian virus 40 large T antigen. Only yeast cells
cotransformed with hPIP1 and PAK1 grew on synthetic medium plates defi-
cient in tryptophan, leucine, and histidine. (B) Activation of lacZ reporter gene
in yeast cells cotransformed with hPIP1 and PAK1. p53 and large T antigen
were used as a positive control in the assays. AU, arbitrary units. (C) Binding of
GST-PAK1 with hPIP1 in vitro. (D and E) Coimmunoprecipitation of hPIP1 with
PAK1 in mammalian cells. cDNAs encoding PAK1 and hPIP1 were cotrans-
fected into COS-7 cells. The protein complex was immunoprecipitated (IP) by
specific antibodies and blotted with anti-PAK1 antibody (D) or anti-FLAG M2
monoclonal antibody (E). Preimmune serum or unspecific immuneserum did
not precipitate the two proteins in the assays.
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activity was completely inhibited (Fig. 5A), indicating that hPIP1
acts as a negative regulator of the PAK signaling pathway. A
similar inhibitory effect on AP-1 activation by PAK was ob-
served by using a dominant negative Rac mutant (RacN17),
suggesting that activation of the AP-1 transcriptional reporter is
PAK-specific in the assay. Together, these data demonstrate that
hPIP1 can block Cdc42-mediated JNK activation by interacting
with PAK1.
hPIP1 Inhibited PAK-Induced NF-kB Activity. PAKs are also known
to be involved in the activation of NF-kB by interacting with the
NF-kB-inducing kinase (NIK) (19, 20). Transient transfection of
PAK1 activated the expression of an NF-kB-dependent reporter
gene in COS-7 cells (Fig. 5B). Dominant activators of PAK1,
Cdc42V12 or RacV12, further activated the NF-kB-dependent
transcriptional activation (Fig. 5B). However, cotransfection of
hPIP1 with PAK1 in the cell blocked the PAK1-induced NF-kB
transcriptional activation as assayed by the luciferase activity
(Fig. 5B), suggesting that hPIP1 inhibits the PAK1-coupled
NF-kB signaling pathway.
hPIP1 Interacts with the N-Terminal Regulatory Domain of PAK1 to
Modulate Its Function. Recent studies demonstrate that PAK
forms an asymmetric dimer in the autoinhibited conformation,
held together by the interaction of the autoregulatory fragments
(23). The domain structure and organization of PAK proteins
suggest multiregulatory mechanisms for the activation of the
kinases (Fig. 6A). Binding of Cdc42 or Rac to PAK disrupts the
‘‘inhibitory switch’’ (IS) domain, thereby relieving the kinase
inhibition by breaking the dimer contact (23). A similar mech-
anism of activation by Cdc42yRac was demonstrated for Wis-
kott–Aldrich syndrome protein (36). To identify which do-
main(s) of PAK1 interacts with hPIP1, we generated a number
of GST fusion proteins corresponding to different domains of
PAK1 (Fig. 6B). The purified GST-PAK fusion proteins were
used in GST pull-down assays with in vitro transcribed and
Fig. 4. hPIP1 inhibits Cdc42-stimulated PAK1 activity. (A) Inhibition of
Cdc42-stimulated PAK1 activity by hPIP1 in mammalian cells. Cell lysates from
COS-7 cells expressing proteins as shown were immunoprecipitated with
specific anti-PAK1 antibody to isolate PAK1, and were then subjected to
protein kinase assays using myelin basic protein (MBP) as substrate. Bottom
band shows that the amount of PAK1 used in the reaction was constant, as
assayed by Western blot analysis. (B) hPIP1 had little effect on the kinase
activity of PAK1 mutant (PAK1T423E). (C) hPIP1 inhibited GTPgS-Cdc42-
mediated PAK1 activity in vitro. A fixed amount of PAK1 was activated by 2 mg
of GTPgS-loaded Cdc42 in the presence or absence of hPIP1 (4 mg per reaction)
with MBP as a substrate (4 mg per reaction). (D) Inhibition of Cdc42- and
PAK1-mediated JNK activation by hPIP1. Cotransfection of hPIP1 greatly
inhibited the activation of HA-JNK by Cdc42 (V12) or Cdc42 together with
PAK1. JNK kinase was immunoprecipitated by anti-HA monoclonal antibody,
and GST-cJun (2 mg, amino acids 1–79) was used as a phosphorylation sub-
strate. Equal amounts of JNK were used in the assays, as shown in the bottom
band by Western blot analysis.
Fig. 5. Regulation of PAK1-induced AP-1 and NF-kB signaling pathways. (A)
Overexpression of hPIP1 blocks Cdc42-PAK1-stimulated AP-1 transcriptional
activity. COS-7 cells were cotransfected with either empty vector (lane 1) or
cDNAs encoding the listed proteins, together with the reporter pAP1-Luc. RU,
relative light units. (B) hPIP1 inhibited the activation of NF-kB transcriptional
activity by PAK1 or PAK1 plus Cdc42 in the reporter assays. In the control
experiment (lane 1), the cells were transfected with pCMV-lacZ plasmid. The
results are expressed as the mean of values determined from at least three
independent transfection assays.








translated hPIP1. As shown in Fig. 6C, hPIP1 binds strongly with
full-length PAK1 and the PAK1 N-terminal domain (residues
1–70), and to a lesser degree with the autoregulatory domain
(residues 70–150). Little or no interaction was detected for the
PIX-binding domain, the kinase domain, and the putative Gbg-
binding motif of PAK1, suggesting that hPIP1 interacts with
PAK1 through the N-terminal regulatory region of the PAK1
protein. The N-terminal region of PAK1 (residues 1–149) con-
tains the Nck binding motif, the dimerization domain (Di), the
inhibitory switch (IS) domain, and the kinase inhibitor segment
(KI). Intact PAK1 forms an inactive dimer held together by the
autoregulatory fragments with the IS domain inhibiting the
kinase with one surface and anchoring the dimer contact with
another (23). Other studies have suggested a role for the
N-terminal regions of PAKs in negatively regulating kinase
activity (24). Therefore, interaction of hPIP1 with the N-
terminal regulatory domain of PAK1 could stabilize the protein
in the inactive dimeric conformation.
Overexpression of hPIP1 Affects Cell Shape and Cytoskeletal
Organization. To study the potential role of hPIP1 in regulating
cytoskeletal organization, we examined cellular morphology and
cytoskeletal organization in mouse embryonic fibroblasts ex-
pressing FLAG-tagged hPIP1. As shown in Fig. 7, the cell
expressing the FLAG-tagged hPIP1 has an abnormal morphol-
ogy as compared with cells not transfected by hPIP1 (Fig. 7A).
We further examined the organization of the actin filaments in
the cells expressing FLAG-hPIP1 by using rhodamine-
conjugated phalloidin (Fig. 7B). Cells expressing hPIP1 showed
much more rounded cell shape and reorganized actin stress
fibers, suggesting a potential role of this protein in actin cy-
toskeletal organization.
Discussion
Protein kinases are often subject to multiple levels of regulation.
The involvement of PAKs in gene expression, cytoskeletal
architecture, neuronal cell growth, and cellular apoptosis re-
quires that their activities be tightly controlled. We have de-
scribed the identification and characterization of a human
PAK1-interacting protein, hPIP1, that contains five Gb-like WD
repeats and a C-terminal positively charged domain. The inter-
action of hPIP1 with PAK1 and the negative regulation of PAK1
activity have important implications for the understanding of
PAK and PAK-mediated signaling pathways. Activation of PAK
and PAK signaling pathways has been reported for a number of
different proteins (Cdc42yRac, adaptor protein Nck, exchanger
factors PIX and Cool, and Gbg in yeast cells; refs. 1, 27, and
31–33). However, relatively little is known regarding the negative
regulation of PAK. Our data demonstrate that hPIP1 interacts
with the N-terminal regulatory domain of PAK1 and negatively
Fig. 6. Identification of PAK1 domain(s) responsible for the interaction with
hPIP1. (A) Domain structure of the PAK1 polypeptide chain. The N terminus
(residues 1–69) was identified as interacting with Nck. The autoregulatory
regions (residues 70–149) contain the dimerization segment (Di), the p21
binding domain (PBD), the inhibitory switch domain (IS), and the kinase
inhibitory segment (KI). The C terminus contains the kinase domain and the
Gbg-binding motif. (B) GST-PAK1 fusion proteins. Numerals indicate residue
numbers at the boundaries of various subdivisions. (C) Interaction of different
GST-PAK1 domains with in vitro translated hPIP1. HPIP1 interacts with the full
length PAK1, the N-terminal domain (residues 1–70), and the autoregulatory
domain (residues 70–149). The PIX-binding domain and the C-terminal region,
including the kinase domain and the Gbg-binding motif, are not involved in
the hPIP1 association. Bottom band shows that the same amount of 35S-
labeled hPIP1 was used in the binding assays.
Fig. 7. Effects of hPIP1 overexpression in mouse embryo fibroblasts. (A) Cells transfected with FLAG-tagged hPIP1 and stained with anti-FLAG monoclonal
antibody (M2, Sigma). Arrow indicates the cell overexpressing FLAG-hPIP1. (B) Immunofluorescence image of actin filaments with rhodamine-phalloidin staining.
Arrow indicates the fibroblast cell overexpressing hPIP1 protein.
6178 u www.pnas.orgycgiydoiy10.1073ypnas.101137298 Xia et al.
modulates PAK and PAK-mediated signaling pathways in mam-
malian cells. In fission yeast, a null mutation of the hPIP1
homolog, the Skb15 gene, is lethal and results in severe dereg-
ulation of both actin and microtubule cytoskeletons (37). hPIP1
was identified initially as interacting with PLC-b3 in the yeast
two-hybrid assays. The exact role of this protein in PLC-Ca21
signaling is not clear.
It has been demonstrated that PAK1 exists as a dimer in an
autoinhibitory conformation. Mutation at a specific Thr site of
PAK1 (T423E) could disrupt the dimeric structure and change
the autoinhibitory conformation of the PAK protein, leading to
the autophosphorylation of PAK1 at multiple sites, and conse-
quently, the creation of a constitutively active protein kinase. If
hPIP1 binds to the inactive conformation of PAK1 and is
involved in the activation process by Cdc42yRac, then we expect
that hPIP1 has little effect on the constitutively active mutant of
PAK1 (PAK1T423E), as shown in our experimental results. The
ability of the hPIP1 protein to interact with PAK1 through
the N-terminal regulatory domain provides a mechanism for the
inhibition of the kinase at the molecular level. The fact that
hPIP1 negatively modulates PAK-mediated JNK and NF-kB
signaling pathways suggests a new mode of regulation for
PAK-mediated signal transduction in mammalian cells. Further-
more, overexpression of hPIP1 into fibroblastic cells results in
reorganization of actin cytoskeleton, suggesting that hPIP1 may
be an important regulator for PAK-mediated cytoskeletal orga-
nization. Therefore, understanding of how cells regulate their
cytoskeleton dynamics and morphogenesis through PAK and
other signaling pathways is of great importance for providing
basic molecular mechanisms of cellular functions.
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